Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Bortezomib and dexamethasone after ASCT for high-risk MM

Elena Zamagni • 6 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies Bortezomib Dexamethasone Lenalidomide

Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the use of bortezomib and dexamethasone as maintenance therapy following upfront autologous stem-cell transplantation (ASCT) for high-risk multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Elena Zamagni

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:23
Combining MRD assays with functional imaging in multiple myeloma
Elena Zamagni • 28 Sep 2023
1:21
The impact of MRD standardized assessment by FDG-PET/CT in patients enrolled in the FORTE trial
Elena Zamagni • 28 Sep 2023
2:29
The role of various imaging techniques in multiple myeloma & the importance of optimizing these
Elena Zamagni • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals